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Abstract
Background: The burden of diabetes in Lebanon requires well-targeted interventions for screening type 2 diabetes
mellitus (T2DM) and prediabetes and prevention of risk factors. Newly recruited 998 Lebanese individuals, in
addition to 7,292 already available, were studied to investigate the prevalence of diabetes, prediabetes and their
associated risk factors.
Methods: Participants had fasting blood sugar and glycohemoglobin tests in addition to a lipid profile. Clinical
and demographic information were obtained from a detailed questionnaire. The relationship between T2DM, its
risk factors, and its complications were tested. Comparisons of these risk factors among diabetics, healthy, and
coronary artery disease (CAD) patients were performed.
Results: The prevalence of T2DM significantly increased with increasing BMI (p < 0.0001). Exercise activity level
negatively correlated with the disease (p=0.002), whereas the prevalence of T2DM (p < 0.0001) and CAD family
history (p= 0.006) positively correlated with the affection status. The mean levels of triglycerides and LDL-C were
significantly higher in diabetics (1.87; 1.35) compared to individuals with prediabetes (1.63; 1.26) and unaffected
controls (1.49; 1.19). People with T2DM showed a significant decrease in HDL-C levels. A strong correlation of
overall hyperlipidemia with the diabetes affection status was shown (p < 0.0001). Other comorbid factors such as
hypertension (p < 0.0001) and self-reported obesity (p < 0.0001) were highly associated with T2DM and prediabetes.
Reproductive health of women showed a strong correlation between giving birth to a baby with a high weight and
t h eo c c u r r e n c eo fT 2 D Ma n dp r e d i a b e t e sl a t e ri nl i f e( p<0 .0001). Retinopathy and peripheral neuropathy were
significantly correlated with diabetes and prediabetes (p < 0.0001).
Conclusions: The present study shows an alarming prevalence of diabetes and prediabetes in the studied
subgroups representative of the Lebanese population.
Keywords: Type 2 diabetes, Prediabetes, Lebanon, Risk factors, Hyperlipidemia, Coronary artery disease
Background
According to the International Diabetes Federation (IDF),
32.8 million people or 9.1% of the adult population in
the Middle East and North Africa Region (MENA) had
diabetes in 2011 [1]. A further 24 million people, or
6.7% of the population, are at high risk of diabetes from
impaired glucose tolerance. Six of the 10 countries with
the highest prevalence of diabetes in the world are from
the MENA Region: United Arab Emirates (18.7%),
Saudi Arabia (16.8%), Bahrain (15.4%), Kuwait (14.6%),
Oman (13.4%), and Lebanon (7.7%). By 2025, the num-
ber of people with diabetes is expected to more than
double in these regions. According to the World Health
Organization, the age-standardized mortality rate from
cardiovascular disease and diabetes per year was esti-
mated to be 224 in 2008 in Lebanon, which is 1.2 times
higher than cancer mortality rate.
In spite of the high estimates of diabetes prevalence in
the region, the healthcare expenditures due to diabetes
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governments remain largely unaware of the current
magnitude and future burden of diabetes in their societies
[1]. T2DM in Lebanon would be better managed if we had
a global overview on the prevalence of prediabetes and
diagnosed and undiagnosed diabetes mellitus, coupled
to an estimation of risk factors such as physical inactivity,
obesity, hyperlipidemia, and gestational diabetes mellitus
(GDM). In addition, T2DM and Coronary Artery Disease
(CAD) frequently coexist and are major components of
the public health and economic burden worldwide. An
epidemiologic study targeting risk factors such as phys-
ical inactivity, smoking, and alcohol consumption can
therefore help guiding a proportionate public health re-
sponse to the epidemic of diabetes and CAD. Suscepti-
bility to these complex diseases is strongly influenced
by common environmental factors, but how these fac-
tors act in the Lebanese population remains largely
unknown.
In order to leverage the genetic information from prior
studies in this laboratory, it is desirable to pool prior
CAD data with data collected specifically for T2DM.
A difficulty is that the enrollment criteria were strik-
ingly different. The CAD study subjects were all en-
rolled from a pool of catheterized patients. Since
catheterization is an invasive procedure, all subjects,
whether or not they ultimately showed luminal narrow-
ing, had to showsufficient cause for the catheterization
according to clinical indications and behavior. The
T2DM study enrollment occurred at multiple clinical
sites where recruitment was advertised. This enrollment
included selection of cases versus controls. In order to
associate genetic markers with demographics and dis-
ease in a pooled set of data, the impact of the enroll-
ment criteria was characterized.
The aims of this study are: (1) to estimate the prevalence
of prediabetes, diagnosed and undiagnosed diabetes in the
Lebanese population age 55 or older, (2) to investigate
and identify the risk factors of T2DM and CAD in the
Lebanese population and, (3) to estimate the inferred risk
of known factors to T2DM and CAD patients. Results
from this study will help policy makers and health practi-
tioners in promoting well-targeted prevention programs
to minimize the burden of diabetes mellitus in developing
countries.
Methods
Study population
The study consisted of two phases. In the first phase
of the project we actively recruited 998 subjects in
2012 specifically to survey the prevalence of diabetes
and its risk factors among the Lebanese population. In
the second phase we selected 991 CAD cases from an
existing database that consisted of 7,292 subjects recruited
between 2007 and 2013 to study CAD and associated
diseases such as T2DM and hypertension (FGENT-
CARD - Functional Genomic Diagnostic Tools for Coronary
Artery Disease). The combined phase 1 and phase 2 datasets
were used to study the association of risk factors with
T2DM and CAD and to estimate the inferred risk of
known factors to T2DM and CAD.
An additional CAD-free 1,330 subjects from the FGEN
TCARD database were combined with the subjects from
Phase 1 to further investigate the prevalence of T2DM in
the Lebanese population.
Surveyed population through targeted T2DM campaigns
(Phase 1)
In this phase 998 Lebanese adult subjects were recruited
through two targeted advertisement campaigns for vol-
unteers over the age of 55 to have their blood tested for
diabetes. The first campaign was conducted in the suburbs
of Beirut, the capital of Lebanon, with the collaboration of
the Lebanese American University Medical Center. The
second advertisement campaign was conducted in North
Lebanon where volunteer recruitment was done in five
villages with the help of endocrinologists and local social
workers. Research was carried out in compliance with the
Helsinki Declaration and with the approval of the LAU
Institutional Review Board and local ethics committees on
human research (Reference number SMPZ08072010-4).
All participants signed an approved informed consent.
The consent form stipulated that the participant agreed to
be interviewed and to give a blood sample to be used for
DNA analysis, as well as glycated hemoglobin (HbA1C),
fasting blood sugar (FBS), and lipid profile measurements.
FGENTCARD population (Phase 2)
991 subjects, of which 31.9% were diabetics and 68.1%
were non diabetics were selected from a database that
included 7,292 subjects that were recruited between
2007 and 2013 for inclusion in the FGENTCARD
database. Detailed clinical and demographic information
have been previously described [2] (Additional file 1).
406 out of the 991 participants had >50% stenosis in at
least one vessel and were designated as severe CAD
patients, 207 had stenosis ≤50% in at least one vessel and
were designated as moderate CAD patients, and 378 had
0% stenosis and were classified as controls. Individuals
were chosen to match with the T2DM surveyed popula-
tions for sex (35.6% of males and 64.4% of females) and
mean age (63.9 for severe stenosis; 65.9 for moderate
and mild stenosis and 63.7 for unaffected controls).
The subjects from Phase 1 were compared to a stenosis-
free population of 1,330 clinically well-characterized sub-
jects selected from the FGENTCARD database. From the
1,330 selected controls, 664 were more than 55 years old.
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In order to measure the height and weight of all partici-
pants, a calibrated mass was placed on a scale. The known
mass value was compared to the scale reading and the
percent error was calculated to determine the acceptability
of the balance or scale prior to height and weight mea-
surements. The height and weight were used to calculate
the body mass index (BMI). The blood samples were
collected by well-trained phlebotomists.
For the surveyed population, blood samples were col-
lected for Glycated Hemoglobin 1C (HbA1C) testing,
FBS and lipid profile assays. HbA1C, Fasting Blood
Sugar (FBS) and lipid profile assays were performed on
COBAS INTEGRA 400 Plus as follows: HbA1c levels
were determined using an immunoturbidimetric assay,
FBS was measured via an enzymatic reference method
using the hexokinase, and the lipid panel (total choles-
terol (TC), triglycerides, HDL-cholesterol (HDL-C), and
LDL-cholesterol (LDL-C)) was measured according to
the absorbance photometry principle via enzymatic col-
orimetric methods.
For the FGENTCARD population, cardiologists perform-
ing the coronary angiography collected a 20 mL blood
sample from the peripheral femoral artery of patients.
Annotations were coded from medical charts according
to the study protocol, which included results of laboratory
tests, prescribed medications, and presence of other
diseases and conditions.
Measurement of variables
BMI was calculated according to standard measurements.
A BMI of 25–30 kg/m
2 indicated overweight and a BMI
of ≥30 kg/m
2 was an indicator of obesity. FBS was catego-
rized according to glucose level: 70–99 mg/dL, normal
fasting glucose; 100–125 mg/dL, impaired fasting glucose
or prediabetes; and ≥126 mg/dL, diabetes. An HDL-C
level <35 mg/dL was set as an increased risk of T2DM.
For LDL-C, TC, and triglycerides, the threshold levels for
an increased T2DM risk were ≥130 mg/dL, ≥200 mg/dL,
and ≥250 mg/dL respectively in line with standard defini-
tions of hyperlipidemia.
Participants were considered hypertensive if blood
pressure is at or above 140/90 mmHg or if they were on
antihypertensive drugs. Participants were diagnosed with
T2DM if they were clinically documented diabetic patients
on medication (oral hypoglycemic agent or insulin), or
presented with a level of HbA1C of ≥6.5% in line with the
American Diabetes Association (ADA) definition of type 2
diabetes mellitus diagnosis [3]. Individuals with an HbA1C
ranging from 5.7% to 6.4% were considered as prediabetics
with an increased risk of developing diabetes in the future.
Individuals with an HbA1c ≤5.6%. were labeled as healthy
non-diabetic. Participants were considered hyperlipidemic
if they had clinically documented hyperlipidemia with
medication intake, or presented with a level of TC, triglyc-
erides, or LDL-C above the threshold. A family history
was positive when the condition was present in a parent,
sibling, or second degree relative.
Statistical analysis
Data analysis was conducted with the statistical software
package “Statistical Package for Social Sciences” (SPSS)
for windows, version 20, and the glm package from R
version 3.0.2 [4]. Chi square test is used to assess the as-
sociation between two categorical variables and ANOVA
for continuous variables. Odds ratios were obtained using
multinomial logistic regression. For HDL-C, odds ratios
were calculated using the thresholds of HDL-C <35 mg/dL
and of TC/HDL-C ratio ≥4 mg/dL as increased risks for
T2DM and CAD respectively. A p value of 0.05 was con-
sidered to indicate statistical significance.
Impact of enrollment was estimated by applying logistic
regression to predict diagnosis of CAD and T2DM based
solely on study population, where the data were re-parti-
tioned for this analysis (1=CAD study enrollment, 5,359
subjects; 2=T2DM enrollment, 998 subjects, all of both
groups 55 years old or older). Only 177 T2DM enrolled
subjects showed knowledge of CAD state. Enrollment
criteria associations were also explored for behavioral
components (active lifestyle and smoking), as well as clin-
ical variables (diagnoses of hypertension, hyperlipidemia,
high triglycerides, BMI – t h r e s h o l do f3 0 ,a n dH D L ) .
Second, association of enrollment population and behavior
with clinical variables was assessed. Third, an association
test of how metabolic syndrome varies with diagnosis of
T2DM and CAD was performed. Fourth, interactions of
triglycerides with T2DM, and the impact of T2DM on
CAD, were examined. These results are non-tabulated due
to variable format and test structure.
Results
In the surveyed population (Phase 1) 354 (35.6%) were
males and 639 (64.4%) were females (Table 1). The mean
age of the control group is 65 years old which diminishes
the possibility of developing T2DM since the mean age of
onset of T2DM in our cohort was 54.6 years old (±12.4).
T h ep r e v a l e n c eo fT 2 D Ms i g n i f i c a n t l yi n c r e a s e dw i t h
increasing BMI (p < 0.0001) (Table 1).
Out of the 991 subjects selected in phase 2, 353
(35.6%) were males and 638 (64.4%) were females
(Table 2). The mean age of the control group is 64 years
old (±10.5) (n =378) compared to 66 years old (±9.9) in
the moderately affected group (n =207), and 64 years
old (±11.3) in the severely affected group (n =406). Exer-
cise activity level negatively correlated with the disease
(p=0.002), whereas the prevalence of T2DM (p < 0.0001)
and CAD family history (p=0.006) positively correlated
with the affection status (Table 2).
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through the two T2DM advertised campaigns where it is
expected that more diabetics would likely participate,
we selected an additional 1,330 subjects stenosis-free
from the FGENTCARD population. Out of these 687
(51.7%) were males and 643 (48.3%) were females
(Table 3). The mean age of the control group is 55 years
old (±11.9) compared to the mean age of the diabetics
which is 58 years old (±11.6). According to their medical
records, 20.5% of the participants had type 2 diabetes, this
percentage increased to 23.6% when the calculations
included people above 55 years old (Table 4). Studying
risk factors by T2DM diagnostic status confirmed a sig-
nificant association of activity level, BMI, triglycerides,
overall hyperlipidemia, positive T2DM family history, and
hypertension with T2DM (Table 3). Although HDL-C
did not show significant association, there was a trend
towards association of low levels of HDL-C and T2DM
o c c u r r e n c e( T a b l e3 ) .
In the surveyed population (Phase 2) the mean levels
of triglycerides and LDL-C were significantly higher in
diabetics (1.87; 1.35) compared to individuals with predi-
abetes (1.63; 1.26) and unaffected controls (1.49; 1.19)
(Table 5). People with T2DM showed a significant decrease
in HDL-C levels (Table 5). A strong correlation of overall
hyperlipidemia with the diabetes affection status was
shown (p < 0.0001) (Table 6). Other comorbid factors such
as hypertension (p < 0.0001) and self-reported obesity
(p < 0.0001) were highly associated with T2DM and
prediabetes (Table 6). Although cardiovascular disease
status did not show significant results, there was a posi-
tive trend (p=0.08) (Table 6).
Triglycerides mean was significantly higher in patients
with severe CAD compared to patients with mild CAD as
well as healthy unaffected individuals (Table 2). Overall
hyperlipidemia was associated with CAD (p < 0.0001).
Low levels of HDL-C were associated with a severe CAD
affection status (p=0.02) (Table 2).
Table 1 Distribution in the surveyed population of different factors by T2DM diagnosis status
T2DM categories
Diabetics n= 407 Prediabetics n=207 Non-diabetic n=379 Total n=993 p value
No. (%) No. (%) No. (%)
Gender 0.4
Male 154 (37.8) 68 (32.9) 132 (34.8)
Female 253 (62.2) 139 (67.1) 247 (65.2)
Age (Years) mean (SD) 64 (11.4) 66 (9.9) 65 (12.3) 0.09
Age of onset (Years) mean (SD) 55 (12.4) 60 (11.4) NA 0.03
Body Mass Index, mean (SD) 29.1 (5.4) 28.6 (5.1) 27.3 (4.4) <0.0001
Exercise activity level 0.9
Non-active 248 (62.0) 116 (56.9) 215 (60.4)
Moderate activity 58 (14.5) 33 (16.2) 48 (13.5)
Heavy activity 94 (23.5) 55 (27.0) 93 (26.1)
Smoking 0.2
Never smoker 179 (44.8) 103 (50.5) 190 (53.2)
Former smoker 92 (23.0) 43 (21.1) 70 (19.6)
Current smoker 129 (32.3) 58 (28.4) 97 (27.2)
Alcohol consumption 0.003
Never drinker 276 (69.0) 132 (64.7) 219 (61.3)
Less than 7 drinks per week 118 (29.5) 70 (34.3) 119 (33.3)
More than 7 drinks per week 6 (1.5) 2 (1.0) 19 (5.3)
Family history of T2DM
Yes 267 (67.9) 87 (44.4) 158 (47.7) <0.0001
No 126 (32.1) 109 (55.6) 173 (52.3)
Consanguinity 0.96
Yes 69 (17.5) 36 (18.3) 58 (17.4)
No 325 (82.5) 161 (81.7) 276 (82.6)
Abbreviation: T2DM Type 2 diabetes mellitus, SD Standard deviation.
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significantly associated with the diabetes status in the
1330 stenosis free group (Table 3). Subjects with T2DM
showed a trend towards a decrease in HDL-C levels
although this did not reach the level of significance
(Table 3). A strong correlation of other comorbid factors
such as hypertension (p < 0.0001) and obesity (p < 0.0001)
were highly associated withT2DM (Table 3).
Studying reproductive health of women in the surveyed
population showed a strong correlation between giving
birth to a baby with a high weight and the occurrence of
T2DM and prediabetes later in life (p<0.0001) (Table 7).
Retinopathy and peripheral neuropathy were significantly
correlated with diabetes and prediabetes (p<0.0001)
(Table 8). We calculated the odds ratios of T2DM versus
CAD in our T2DM (998 subjects) and CAD (991 subjects)
groups. Figure 1 and Table 9 present an inferred risk of
the major T2DM and CAD risk factors such as physical
activity, smoking, BMI, HDL-C levels, hyperlipidemia,
positive family history, and hypertension. The 1,330
stenosis free subjects replicated and confirmed the in-
ferred risk of the factors found to increase T2DM in our
surveyed population, such as BMI, triglycerides, overall
hyperlipidemia, positive family history of T2DM, and
hypertension. The protective role of physical activity
against T2DM was also confirmed (Table 9).
Population enrollment shows significant association with
T2DM diagnosis (OR=1.41, 95% CI: 1.22 – 1.62, p-value =
Table 2 Distribution in 991 individuals from FGENTCARD of different factors by CAD diagnosis status
CAD categories
Severe CAD n=406 Mild CAD n=207 Healthy n=378 Total n=991 p value
No. (%) No. (%) No. (%)
Gender 0.5
Male 153 (37.7) 68 (32.9) 132 (34.9)
Female 253 (62.3) 139 (67.1) 246 (65.1)
Age (years) mean (SD) 64 (11.3) 66 (9.9) 64 (10.5) 0.04
Body mass index, mean (SD) 29.1 (5.3) 29.7 (5.9) 29.7 (5.8) 0.2
Exercise activity level 0.002
Non-active 85 (21.0) 34 (16.5) 49 (13.1)
Moderate activity 315 (77.8) 163 (79.1) 307 (81.9)
Heavy activity 5 (1.2) 9 (4.4) 19 (5.1)
Smoking 0.01
Never smoker 150 (37.0) 103 (49.8) 185 (49.1)
Former smoker 105 (25.9) 43 (20.8) 81 (21.5)
Current smoker 150 (37.0) 61 (29.5) 114 (29.4)
Family history of CAD
Yes 260 (64.5) 91 (44.2) 174 (46.3) 0.006
No 143 (35.5) 115 (55.8) 202 (53.7)
Consanguinity 0.44
Yes 73 (19.6) 34 (17.2) 60 (16.7)
No 299 (80.3) 163 (82.7) 299 (83.3)
Hypertension 0.1
Yes 263 (64.8) 137 (66.2) 220 (58.5)
No 143 (35.2) 70 (33.8) 156 (41.5)
Hyperlipidemia <0.0001
Yes 227 (56.0) 91 (44.0) 149 (39.5)
No 178 (44.0) 116 (56.0) 228 (60.5)
Type 2 diabetes mellitus <0.0001
Yes 172 (42.4) 59 (28.5) 84 (22.3)
No 234 (57.6) 148 (71.5) 292 (77.7)
Abbreviation: CAD Coronary artery disease, SD Standard deviation.
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−6) where 42% of the case–control selected
T2DM enrollees had a T2DM diagnosis, while 34% of
the CAD study enrollees had T2DM. On the other
hand, there is a significant inverse association of CAD
diagnosis with enrollment in the T2DM study (OR =
0.26, 95% CI: 0.19 – 0.36, p-value <2×10
−16).
Results for variables such as hypertension, obesity and
hyperlipidemia showed different levels of significant
association with population enrollment in T2DM and
CAD cohorts (Additional file 1).
Prediction of T2DM by metabolic syndrome variables,
without or with inclusion of population for adjustment:
hypertension (without: OR =1.61, 95% CI: 1.42 – 1.83,
p-value= 2.31 ×10
−13; with: OR= 1.75, 95% CI: 1.54 – 2.00,
p-value <2× 10
−16), hyperlipidemia (without: OR= 1.53, 95%
CI: 1.35 – 1.72, p-value= 3.33×10
−12; with: OR =1.52, 95%
CI: 1.35 – 1.71, p-value= 7.63×10
−12), triglycerides (without:
OR=1.49, 95% CI: 1.30 – 1.71, p-value=7.82×10
−9;w i t h :
OR=1.48, 95% CI: 1.29 – 1.70, p-value=2.08× 10
−8), BMI
(without: OR=1.17, 95% CI: 1.03 – 1.32, p-value= 0.0127;
with: OR=1.19, 95% CI: 1.05 – 1.35, p-value=0.00515),
and gender (without: OR= 1.06, 95% CI: 0.94 – 1.20,
p-value= 0.322; with: OR= 0.94, 95% CI: 0.82 – 1.07,
p-value= 0.332).
Prediction of CAD by metabolic syndrome variables
computed in a single regression, without or with inclusion
of population for adjustment: T2DM (without: OR=1.85,
95% CI: 1.51 – 2.27, p-value=2.45×10
−9;w i t h :O R=1 . 9 7 ,
95% CI: 1.61 – 2.43, p-value=9.46×10
−11), hypertension
(without: OR=1.41, 95% CI: 1.17 – 1.70, p-value=2.73×
10
−4; with: OR=1.42, 95% CI: 1.17 – 1.71, p-value=
2.63×10
−4), hyperlipidemia (without: OR=1.52, 95%
CI: 1.27 – 1.82, p-value=4.98×10
−6; with: OR=1.56, 95%
CI: 1.30 – 1.86, p-value=1.49×10
−6), triglycerides (with-
out: OR=1.08, 95% CI: 0.87 – 1.34, p-value=0.471; with:
OR=1.09, 95% CI: 0.88 – 1.36, p-value=0.414), BMI
(without: OR=0.87, 95% CI: 0.73 – 1.04 , p-value=0.132;
w i t h :O R=0 . 8 6 ,9 5 %C I :0 . 7 2– 1.03, p-value= 0.107),
and gender (without: OR= 0.26, 95% CI: 0.22 – 1.31,
p-value<2×10
−16; with: OR=0.27, 95% CI: 0.22 – 0.32,
p-value=<2×10
−16).
Table 3 Distribution in 1,330 random FGENTCARD
individuals of different factors by T2DM diagnosis status
T2DM categories
Diabetic
n= 272
Non-diabetic
n= 1,058
Total
n= 1,330
p value
No. (%) No. (%)
Gender 0.008
Male 121 (44.5) 566 (53.5)
Female 151 (55.5) 492 (46.5)
Age (years)
mean (SD)
58 (11.6) 55 (11.9) 0.0002
Body mass index <0.0001
Less than 30 111 (42.2) 645 (62.6)
More or equal to 30 152 (57.8) 385 (37.4)
Exercise activity level 0.007
Non-active 41 (15.1) 93 (8.8)
Moderate activity 214 (79) 886 (83.7)
Heavy activity 16 (5.9) 79 (7.5)
Smoking 0.001
Never smoker 143 (52.6) 433 (40.9)
Former smoker 52 (19.1) 200 (18.9)
Current smoker 77 (28.3) 425 (40.2)
Family history
of T2DM
Yes 190 (69.9) 492 (46.5) <0.0001
No 82 (30.1) 565 (53.5)
Consanguinity 0.6
Yes 56 (21.2) 201 (19.7)
No 208 (78.8) 818 (80.3)
Triglycerides
High level 162 (68.4) 505 (54.9) 0.0002
Normal level 75 (31.6) 415 (45.1)
HDL-cholesterol 0.6
Low level 73 (30.7) 267 (29.0)
Normal level 165 (69.3) 654 (71.0)
Hypertension <0.0001
Yes 197 (72.4) 487 (46.0)
No 75 (27.6) 571 (54.0)
Hyperlipidemia <0.0001
Yes 213 (78.6) 659 (62.3)
No 58 (21.4) 398 (37.7)
Family history of
CAD
0.3
Yes 144 (53.1) 602 (57.0)
No 127 (46.9) 455 (43.0)
Abbreviation: T2DM Type 2 diabetes mellitus, CAD Coronary artery disease;
SD Standard deviation.
Table 4 Distribution of the different populations studied
by T2DM diagnosis status
Diabetic (%) Non-diabetic (%) Total
Surveyed T2DM population 407 (41) 586 (59) 993
FGENTCARD population 2,437 (33.4) 4,855 (66.5) 7,292
Randomly selected
population
272 (20.5) 1,058 (79.5) 1,330
Randomly selected population
(age≥55 years old)
157 (23.6) 507 (76.4) 664
CAD population 2,152 (36.5) 3,748 (63.5) 5,900
Abbreviation: T2DM Type 2 diabetes mellitus, CAD Coronary artery disease.
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Much about the pathology of T2DM and its etiology
remains unknown. Researchers acknowledge that differ-
ent genes and environmental factors may lead to disease
processes that differ from person to person and from an
environment to another. This study unravels some of
the key environmental and behavioral factors that play a
role in T2DM occurrence in the Lebanese population.
Prevalence of T2DM and prediabetes
The small number of males in the survey sample
(35.6%) was due to the fact that most men were at
work at the time of the recruitment. In the randomly
selected population, 51.7% of the participants were
male compared to 48.3 females. Our surveyed popula-
tion consisted of 40.8% diabetics, 20.7% of people with
prediabetes, and 38% of unaffected healthy partici-
pants. The overestimation of affected people is prob-
ably due to the fact that campaigns were organized
mainly with the help of endocrinologists for increasing
T2DM awareness. Thus, people who knew they were
affected and people with a positive family history had
a higher interest in participating. This led us to inves-
tigate a population of 1,330 stenosis free participants
from the FGENTCARD database. Although the preva-
lence of T2DM was not as high as in our surveyed
population, it was 20.5% (Table 4). This confirms that
Lebanon is facing an alarming increase of the preva-
lence of T2DM. This prevalence increased to 23.6%
when we investigated control subjects that were above
55 years of age.
The prevalence of prediabetes was studied in the
surveyed population only, as the information was not
collected for the FGENTCARD participants. In the
Lebanese population, the prevalence of prediabetes
mirrors roughly the international tendency since ap-
proximately one in three U.S. citizens are known to
have prediabetes [5]. Nearly 100% of the participants
accurately self-reported T2DM and only 16% reported
being aware of their pre-affection status (Table 10). These
results indicate as expected that almost all individuals with
T2DM were aware of their affection status, but alarmingly
show that only one in six individuals had a prior know-
ledge of their prediabetes status. Awareness of prediabetes
Table 5 Lipid profile of the surveyed population by T2DM diagnosis status
T2DM categories
Diabetic Prediabetic Non-diabetic Total p value
n=403 n=207 n=377
Mean (SD) Mean (SD) Mean (SD)
Total cholesterol 2.02 (0.45) 2.27 (0.47) 2.19 (0.49) 987 <0.0001
Triglycerides 1.87 (1.15) 1.63 (0.81) 1.49 (0.68) 987 <0.0001
HDL-cholesterol 0.48 (0.13) 0.54 (0.16) 0.53 (0.13) 987 <0.0001
LDL-cholesterol 1.35 (0.45) 1.26 (0.39) 1.19 (0.37) 987 <0.0001
Abbreviation: T2DM type 2 diabetes mellitus, SD Standard deviation.
Table 6 Distribution of comorbid factors in the surveyed population by T2DM diagnosis status
T2DM categories
Diabetic Prediabetic Non-diabetic Total p value
No. (%) No. (%) No. (%)
Hypertension 961 <0.0001
Yes 226 (56.6) 97 (47.5) 139 (38.8)
No 173 (43.4) 107 (52.5) 219 (61.2)
Hyperlipidemia 945 <0.0001
Yes 222 (56.1) 99 (48.8) 133 (38.4)
No 174 (43.9) 104 (51.2) 213 (61.6)
Obesity 946 <0.0001
Yes 142 (36.0) 45 (22.2) 62 (17.8)
No 252 (64.0) 158 (77.8) 287 (82.2)
Cardiac disease 952 0.08
Yes 93 (23.4) 37 (18.2) 60 (17.1)
No 305 (76.6) 166 (81.8) 291 (82.9)
Abbreviation: T2DM Type 2 diabetes mellitus.
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prediabetes are at high risk for developing T2DM and
11% of persons with prediabetes who do not engage in
moderate physical activity and do not lose weight will
progress to T2DM [6].
Young onset of type 2 diabetes
A feature characterizing T2DM in the Lebanese popula-
tion is the tendency to develop young onset diabetes. A
multiethnic population-based cohort from Canada noted
that the median age at diagnosis of diabetes was lower
by 3 years in Chinese compared to Caucasians (55 years
vs. 58 years) [7]. In our surveyed population the mean
age of onset of T2DM was of 55 years and thus 3 years
less than the median age at diagnosis in Caucasians,
although it is still higher than the mean age of diagnosis
of T2DM in East Asia that is typically around 50 years
(Table 1) [8]. The young age at diagnosis may be due to
an increasingly overweight population as well as the rise
in caloric and fat intake in a region where exercise is not
a defining part of the culture [9].
Reproductive health of females and intrauterine
environment
Once diagnosed with gestational diabetes mellitus, women
are seven times more likely to develop T2DM during their
lifetime compared with women without GDM history [10].
Because the information about GDM is largely missing in
our cohort, we investigated the number of women who
gave birth to a baby weighing more than 4 kilograms
(9 pounds), since GDM and hyperglycemia in pregnancy
have long been related to excessive fetal growth [11-14].
Table 7 Data on reproductive health of females in the surveyed T2DM and prediabetes populations
T2DM categories
Diabetic Prediabetic Non-diabetic Total p value
No. (%) No. (%) No. (%)
Gestational diabetes 484 0.3
Yes 9 (4.3) 2 (1.9) 3 (1.8)
No 199 (95.7) 105 (98.1) 166 (98.2)
Baby weighing >4 kgs at birth 475 <0.0001
Yes 75(37.3) 26 (23.9) 28 (17.0)
No 126 (62.7) 83 (76.1) 137 (83.0)
Polycystic ovary syndrome 544 0.3
Yes 9 (3.9) 6 (4.8) 14 (7.4)
No 222 (96.1) 118 (95.2) 175 (92.6)
Abbreviation: T2DM Type 2 diabetes mellitus.
Table 8 Distribution of reported health complications in the surveyed population by T2DM diagnosis status
T2DM categories
Diabetic Prediabetic Non-diabetic Total p value
No. (%) No. (%) No. (%) 944 0.0008
Retinopathy
Yes 41 (10.4) 10 (5.0) 13 (3.7)
No 354 (89.6) 192 (95.0) 334 (96.3)
Peripheral neuropathy 944 0.005
Yes 61 (15.5) 25 (12.3) 27 (7.8)
No 332 (84.5) 178 (87.7) 321 (92.2)
Liver disease 948 0.4
Yes 18 (4.5) 5 (2.5) 11 (3.2)
No 378 (95.5) 198 (97.5) 338 (96.8)
Skin condition* 948 0.6
Yes 17 (4.3) 7 (3.4) 10 (2.9)
No 380 (95.7) 196 (96.6) 338 (97.1)
*Skin condition includes eleven psoriasis, six fungal infections, five dark spots on the skin, three vitiligo cases, three eczema, two lichen planus rashes, two back
lipomas, and two itchy eruption of the skin. Abbreviation: T2DM Type 2 diabetes mellitus.
Ghassibe-Sabbagh et al. Diabetology & Metabolic Syndrome 2014, 6:89 Page 8 of 12
http://www.dmsjournal.com/content/6/1/89The link between birth weight and adult risk of T2DM
has been observed in our cohort making it a general state-
ment across different ethnicities. This is of particular
concern since a comparison to offspring of normogly-
cemic mothers shows that offspring of mothers with
GDM have increased adiposity at birth and increased
risk of diabetes and obesity later in life [15,16]. Given
the potential transgenerational effects of maternal hyper-
glycemia, GDM screening, diagnosis and treatment should
be routinely practiced in the Lebanese hospitals.
Lifestyle environmental and comorbid risk factors
When participants from the surveyed population were
asked about their weight, 26.3% admitted to be over-
weighed while 73.7% estimated not to have excess weight
(Table 10). BMI measures showed that significantly more
participants were overweight than what is self-reported
with only 23.5% of the participants having normal weight,
37.1% and 30.1% being overweighed and obese respect-
ively. BMI measures showed a significant association of
overweight and obesity with diabetes. Physical activity was
less frequent in diabetics compared to healthy participants
but did not show statistically significant association with
T2DM. The protective role of physical activity, as well as
the association of a BMI ≥30 with T2DM were further
confirmed in our stenosis free population underlining
the increased risk of disease occurrence in the Lebanese
population. These findings highlight the urgent need
for timely interventions promoting physical activity and
weight control nationwide since Lebanon shows high
prevalence of overweight and obesity comparable with
those observed in developed countries [17].
Positive family history of T2DM was one of the most
significant factors predisposing to diabetes occurrence in
our study population underscoring the need for screening
in individuals with family history. One of the reasons to
screen for diabetes is that it has an asymptomatic phase for
which screening can be helpfuli np r e v e n t i n gm a j o rh e a l t h
problems in a sizable portion of the population [18].
Hypertension was positively associated with diabetes in
the different cohorts. Since both hypertension and T2DM
affect the same major target vascular tree, lowering blood
pressure should be the primary goal in the management
of the hypertensive diabetic patients. Comorbid factors
such as hyperlipidemia and low HDL-C levels increased
the risk of T2DM. T2DM is known to be associated with
plasma lipid and lipoprotein abnormalities, including
reduced HDL-C, and elevated triglycerides [19]. Predia-
betics also exhibit an atherogenic pattern of risk factors
that includes higher levels of TC, LDL-C, and triglycerides
and lower levels of HDL-C [20,21]. These plasma lipid
and lipoprotein associated abnormalities contribute to the
risk for atherosclerosis in the majority of patients with
type 2 diabetes [22]. Although we reproduced the positive
Figure 1 Risk factors for type 2 diabetes mellitus and coronary artery disease. Odds ratios and confidence intervals are shown for T2DM
(light grey) and CAD (dark grey) respectively. For each risk factor, a p value shows significance for T2DM and CAD respectively. HDL-C was analyzed as
a categorical variable with a threshold of ≥35 mg/dL for increased T2DM risk. A ratio of TC/HDL-C ≥4 increased risk of CAD. Abbreviations: T2DM, type
2 diabetes mellitus; CAD, coronary artery disease; BMI, body mass index; HDL-C, HDL-cholesterol; TGs, triglycerides; Fx, family history; NA, not applicable.
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stenosis free participants, HDL-C did not show a signifi-
cant protective role, but rather a tendency towards lower
levels in individuals withT2DM (Table 3).
In the surveyed sample, peripheral neuropathy and retin-
opathy were the two complications significantly associated
w i t hT 2 D M .T h i si se x p e c t e ds i n ce peripheral neuropathy,
a common microvascular complication of diabetes [23], is
often associated with concomitant retinopathy [24].
T2DM versus CAD
There is a close relationship between T2DM and CAD
since patients with T2DM have a two to four fold higher
risk of a cardiovascular event with a faster progression
when compared with non-diabetic patients [25]. Compar-
ing our T2DM surveyed cohort to an age and sex-matched
previously described Lebanese CAD cohort confirmed
that the presence of cardiac disease increased the risk
of T2DM by 1.48 fold, whereas T2DM increased the
risk of severe CAD by 2.56 fold. Studying other known
environmental risk factors confirmed that the risk of
severe CAD is increased with sedentary life, smoking,
decreased HDL-C level, hyperlipidemia, and positive
CAD family history. Hence, there is a growing need to
emphasize early and vigilant risk factor management in
patients with T2DM and CAD to help reduce their
morbidity and mortality.
Smoking correlates with hypertension in a generally
surveyed population, including diabetics, but is anti-
correlated among subjects that reached the stage of
Table 9 Unadjusted OR of association of selected risk factors
T2DM (n=998) Severe CAD (n=991) T2DM (n= 1,330)
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Physical activity (Ref: Inactive people)
Active people 0.88 0.62-1.23 0.4 0.15 0.05-0.43 0.0004 0.46 0.24-0.88 0.02
Moderately active people 1.1 0.66-1.83 0.7 0.59 0.40-0.87 0.008 0.55 0.37-0.81 0.003
Smoking (Ref: Non-smokers)
Current Smoker 1.41 1.01-1.97 0.04 1.86 1.30-2.66 0.001 0.55 0.40-0.75 0.0001
Ex-Smokers 1.4 0.96-2.02 0.08 1.23 0.73-2.08 0.4 0.79 0.55-1.13 0.2
BMI (Ref: < 30)
≥ 30 1.08 1.04-1.11 <0.0001 0.98 0.95-1.01 0.1 2.29 1.74-3.02 <0.0001
HDL-cholesterol (Ref: Healthy)
Yes 0.39 0.22-0.69 0.001 0.86 0.76-0.96 0.01 1.08 0.79-1.48 0.6
Triglycerides (Ref: Healthy)
Yes 1.66 1.37-2.00 <0.0001 1 1.00-1.01 0.001 1.78 1.31-2.40 0.0002
Hyperlipidemia (Ref: Healthy)
Yes 2.04 1.52-2.74 <0.0001 1.95 1.47-2.59 <0.0001 2.22 1.62-3.04 <0.0001
Family history of CAD (Ref: No family history of CAD)
Yes 0.93 0.70-1.25 0.6 1.57 1.17-2.09 0.002 0.86 0.66-1.12 0.3
Family history of T2DM (Ref: No family history of T2DM)
Yes 2.32 1.71-3.14 <0.0001 1.22 0.92-1.61 0.2 2.66 2.00-3.54 <0.0001
Hypertension (Ref: Healthy)
Yes 2.06 1.54-2.75 <0.0001 1.3 0.98-1.74 0.07 3.08 2.30-4.12 <0.0001
Coronary artery disease (Ref: Healthy)
Yes 1.48 1.03-2.12 0.03 NA NA NA NA NA NA
Type 2 diabetes mellitus (Ref: Healthy)
Yes NA NA NA 2.56 1.87-3.49 <0.0001 NA NA NA
ORs are calculated among individuals having T2DM compared to non-diabetic and having severe CAD compared to no stenosis as outcome variables.
Abbreviation: T2DM Type 2 diabetes mellitus, CAD Coronary artery disease, OR Odds ratio, BMI Body mass index, Ref Reference.
Table 10 Self-reported T2DM, prediabetes, and excess
body weight in the surveyed population
Reported
condition
Not reported
condition
Total
No. (%) No. (%)
Self-reported T2DM 405 (42.2) 555 (57.8) 960
Self-reported prediabetes 35 (4.1) 825 (95.9) 860
Self-reported weight excess 250 (26.3) 701 (73.7) 951
Abbreviation: T2DM Type 2 diabetes mellitus.
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variables and T2DM also show interactions between
populations. This suggests that the course of progression
and treatment leading to catheterization include behav-
ior modifications impacting correlations between these
populations.
Contrary to the behavioral variables, the prediction of
both T2DM and CAD by metabolic syndrome variables
appears to be unaffected by population, even though the
proportions of these variables in the two populations are
different.
While T2DM, as a part of the metabolic syndrome
complex, is a strong predictor of CAD, the associations
between behavioral contributions and disease are strongly
impacted by progression of disease and treatment.
Comparison with previous studies
A previous study aimed to determine the prevalence of
diagnosed and undiagnosed diabetes in Greater Beirut
in 2005 [26]. From a total of 3,000 exclusively Lebanese
citizens with a mean age of 55.5, 11.3% were found to have
previously diagnosed diabetes and 5.1% had undiagnosed
diabetes. The combined prevalence of previously diagnosed
and newly diagnosed diabetes was 15.8%. In the U.S., 6.3%
of the population had diabetes: 4.5% diagnosed and 1.8%
undiagnosed [27]. The ratio of known to unknown diabetes
obtained in the Lebanese study was similar to the one
recognized in the U.S at that time. Our results show
that the prevalence of diagnosed diabetes in Lebanon
had a sharp increase (2.6 fold in the surveyed population
and 1.5 fold for the randomly selected population) among
people≥ 55 years old for both sexes. A comparable
increase is seen in the U.S. where the prevalence of
diagnosed diabetes increased 2.3 times from 1990 to
2010 [28]. This study provides evidence that there is a
severe epidemic of diabetes including self-reported diag-
nosed and undiagnosed diabetes. These results underscore
the urgent need for planning and delivering primary pre-
vention to the Lebanese population.
Conclusions
In conclusion, our study evaluates the number of predia-
betics, diagnosed and undiagnosed T2DM in a group of
the Lebanese participants. It shows a significant role for
BMI, and positive family history in the predisposition to
prediabetes and T2DM. It confirms comorbid factors such
as hypertension, hyperlipidemia, and low levels of HDL-C
to be associated with an increased risk of prediabetes and
T2DM. It shows the effect of the in utero environment on
the risk of T2DM later in life and gives an overview of the
complications of T2DM in the Lebanese population. It
compares well known risk factors in T2DM and CAD
occurrence measuring odds ratios, showing the link be-
tween these two diseases that could be partly determined
by an unhealthy lifestyle habits as overweight and physical
inactivity. The results suggest the need to further educate
the general public about the risk factors, complications
and severity of T2DM and CAD prior to the development
of disease. Observed associations between behaviors
and disease depend heavily on progression of disease
and treatment. Specifically, more advanced CAD and
T2DM subjects enrolled through catheterization tend
to have a negative association with smoking than those
enrolled through advertisement in the T2DM cohort.
The strongest correlations, regardless of enrollment,
were between metabolic syndrome and T2DM.
Additional file
Additional file 1: Collection of data and demographic characteristics.
A questionnaire gathered data on each subject’s demographic characteristics
such as age, sex, marital status, origin, and parental consanguinity. Data on
behavioral risks factors, smoking status, alcohol consumption and exercise
pattern was also obtained. Results. Association of behavioral variables such
as hypertension, smoking, obesity, and hyperlipidemia, with population
enrollment.
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